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cells from TRAIL-induced apoptosis but does not
contribute to malignant ascites-mediated
attenuation of TRAIL-induced apoptosis
Denis Lane, Isabelle Matte, Claudine Rancourt and Alain Piché*Abstract
Background: Resistance to apoptosis is a major problem in ovarian cancer and correlates with poor prognosis.
Osteoprotegerin (OPG) is a secreted factor in malignant ascites and acts as a decoy receptor for receptor activator
of NF-κB ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TRAIL promotes
apoptosis in ovarian cancer cells. Ovarian cancer ascites attenuate TRAIL-induced apoptosis raising the possibility
that OPG contained in ascites may abrogate the anti-tumor activity of TRAIL.
Methods: Determination of OPG levels in ascites was measured by ELISA. Effect of OPG on TRAIL-induced cell
death was determined by XTT and colony forming assays in ovarian cancer cell lines and primary tumor cells.
Apoptosis was assessed by ELISA.
Results: We found that recombinant OPG and malignant ascites attenuates TRAIL-induced cell death and apoptosis
in a dose-dependent manner in ovarian cancer cell lines and primary ovarian tumor cells. OPG is present at high
levels in the ascites of patients with ovarian cancer. We found a positive correlation between the levels of OPG in
ascites and the ability of the ascites to attenuate TRAIL-induced cell death. The anti-apoptotic effect of ascites was
not reversed by co-incubation with an OPG blocking antibody.
Conclusions: OPG and malignant ascites protect ovarian cancer cells from TRAIL-induced apoptosis. Although
malignant ascites contain high levels of OPG, OPG is not a critical component that contributes to ascites-mediated
attenuation of TRAIL-induced apoptosis.
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Ovarian cancer (OC) is the fifth cause of cancer-related
death in women, the second most common gyneco-
logical cancer, and the leading cause of death from
gynecological malignancies [1,2]. Over 70% of patients
with OC present with late stage disease, with dissemin-
ation of tumor implants throughout the peritoneal cavity
[1-4]. Only 10-15% of these patients maintain complete
response after standard first line treatments, implying
that most patients will relapse. Indeed, the five-year sur-
vival of patients with late stage disease remains at < 30%* Correspondence: alain.piche@usherbrooke.ca
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reproduction in any medium, provided the orwith a median survival of 39 months [5]. One of the
main obstacles to effective treatment is the failure of ini-
tial therapy to eradicate a sufficient number of tumor
cells to prevent disease recurrence.
One of the new promising anti-cancer therapies for
OC is the tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) [6]. TRAIL is a member of
the tumor necrosis factor family and has the ability to
selectively induce apoptosis in tumor cells with little
toxicity to normal cells. TRAIL has been shown to in-
duce apoptosis in a wide range of tumor cells in vitro
and in vivo, including OC cells [7-14]. TRAIL triggers
apoptosis by interacting with TRAIL death receptors
expressed by target cells. TRAIL binds to multipled. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Lane et al. Journal of Ovarian Research 2012, 5:34 Page 2 of 9
http://www.ovarianresearch.com/content/5/1/34receptors including TRAIL R1 (DR4), TRAIL R2
(DR5), TRAIL R3 (DcR1), TRAIL R4 (DcR2) [15-18].
Only TRAIL R1 and TRAIL R2 transmit an apoptotic
signal. In contrast, TRAIL R3 and TRAIL R4 act as
decoy receptors and are incapable of transmitting an
apoptotic signal. Soluble TRAIL also binds with low
affinity to soluble osteoprotegerin (OPG) [19]. Binding
of TRAIL to its death receptors allows the recruitment
of Fas-associated protein with death domain (FADD)
and pro-caspase 8/10 leading to the formation of the
death-inducing signaling complex (DISC). In OC cells,
activated caspase-8 cleaves pro-apoptotic Bcl-2 family
member Bid to form truncated Bid (tBid), which can
then interact with Bax/Bak leading to mitochondrial
permeabilization and activation. This interaction in-
creases the release of cytochrome c from the mito-
chondria resulting in the downstream activation of
effector caspases [20].
OPG is a secreted member of the TNF receptor super-
family. It can bind to the receptor activator of NFκB lig-
and (RANKL) and functions as a soluble decoy receptor
for RANKL. OPG regulates the homeostasis of bone
remodeling by preventing RANKL from binding to its
receptor RANK [21]. OPG also acts as a decoy receptor
of TRAIL and neutralizes its function [19]. Several
reports have shown that OPG is a survival factor and
can block TRAIL-induced apoptosis in tumor cells. For
example, human prostate cancer cells were shown to se-
crete OPG at concentrations sufficient to inhibit TRAIL-
induced apoptosis in vitro [22,23]. Similarly, multiple
myeloma cells were protected from TRAIL-induced
apoptosis by OPG produced from osteoblast-like cells
and bone marrow stroma cells [24]. OPG produced by
breast cancer cells enhances tumor cell survival in vitro
and in vivo by inhibiting TRAIL-induced apoptosis
[25-28]. The production of OPG in colorectal cancer
cells and the addition of exogenous OPG to colorectal
cancer cells both caused resistance to TRAIL-induced
apoptosis [29]. The secretion of OPG in the bone micro-
environment by either tumor cells or bone marrow stro-
mal cells thus appears to be a critical survival factor for
tumor cells. Furthermore, the production and release of
OPG into the serum is higher in patients with late stage
metastatic colon and prostate cancers suggesting that
OPG might exert anti-apoptotic effect during the meta-
static process [29,30]. This is further supported by the
observation that overexpression of OPG is associated
with significantly worse overall survival and relapse-free
survival in colon cancer patients [31]. Moreover, overex-
pression of the OPG protein is an independent risk fac-
tor for colon cancer recurrence [31].
Recent data suggest that malignant ascites can affect
tumor cell behavior by promoting cell growth, invasion,
and survival [32-34]. Specifically, ascites from patientswith advanced OC exert a protective effect against
TRAIL- and drug-induced apoptosis by inducing sur-
vival pathways in tumor cells [32,33,35]. In addition, the
presence of high levels of OPG in malignant ascites was
recently associated with shorter progression-free survival
in patients with OC [36]. These observations raise the
possibility that OPG may protect OC cells from TRAIL-
induced apoptosis and that OPG production in malig-
nant ascites may be a critical survival factor. In this
study, we assessed whether recombinant OPG attenuates
TRAIL-induced apoptosis in OC cell lines and primary
tumor cells. In addition, we determined whether OPG in
ascites facilitates survival of OC cells.
Methods
Malignant ascites, primary tumor cells and cell lines
The study was approved by the institutional review board
of the Centre Hospitalier Universitaire de Sherbrooke.
Informed consent was obtained from women that under-
gone surgery by the gynecologic oncology service for
OC. Malignant ascites were obtained at the time of initial
cytoreductive surgery for all patients. All ascites were
supplied by the Banque de tissus et de données of the
Réseau de Recherche en Cancer of the Fonds de la
Recherche en Santé du Québec (FRSQ) affiliated with the
Canadian Tumor Repository Network (CTRNet). Malig-
nant ascites were centrifuged at 1000 rpm for 15 min
and supernatants were stored at −20°C until assayed for
protein content or XTT. Primary tumor cells were iso-
lated as follow: ovarian cancer ascites were centrifuged at
1000 rpm for 15 min and cells were washed twice with
OSE medium (Wisent, St-Bruno, Québec, Canada). Cells
were then resuspended in OSE medium supplemented
with 10% FBS, β-estradiol (10-8 M), 2 mM glutamine,
antibiotics and fungizone and plated into 75 cm2 flasks.
All floating cells were removed the next day. Tumor cell
samples were used at low passage (< 10). All primary
tumor cells were obtained from patients with advanced
serous OC. To ensure that these cells were tumor cells,
they were stained with epithelial tumor markers anti-
CA125 and cytokeratine 8/18 and with fibroblast specific
marker fibroblast antigen. As shown in Additional file 1:
Figure S1, the human fibroblastic cell line HFL-1 (control)
was positive for fibroblast antigen but negative for cytoker-
atine 8/18 as expected. In contrast, primary tumor cells
OVC215A and OVC399A stained positive for cytokeratine
8/18 and CA125 and negative for fibroblast antigen, con-
firming that most cells are tumor cells. The OC cell lines
CaOV3 and OVCAR3 were obtained from American Type
Culture Collection, (Manassas, VA) and maintained in a
humidified 5% CO2 incubator at 37°C. Cells were passaged
twice weekly. OVCAR3 cells were maintained in RPMI-
1640 (Wisent, St-Bruno, QC, Canada) supplemented with
20% FBS, insulin (10 mg/L), glutamine (2 mM) and
Lane et al. Journal of Ovarian Research 2012, 5:34 Page 3 of 9
http://www.ovarianresearch.com/content/5/1/34antibiotics. CaOV3 cells were cultured in DMEM/F12
(Wisent) supplemented with 10% FBS, 2 mM glutamine
and antibiotics.
Reagents
Recombinant human TRAIL was purchased from
PeproTech. (Rocky Hill, NJ). Recombinant human
OPG and the anti-OPG neutralizing antibiody was
purchased from R&D Systems (Mineapolis, MN).
XTT reagent (2,3-bis-(2-methoxy-4-nitro-5-sulfo-phenyl)
2H-tetrazolium-5-carboxonilide) was from Life Technol-
ogy (Burlington, ON). The specific fibroblast antigen anti-
body was from Oncogen Research Product (clone AS02)
(San Diego, CA). Anti-CA125 (M11) was from Dako
(Burlington, ON) and anti-cytokeratine 8/18 antibody was
from ZYMED laboratories Inc. (San Francisco, CA).
Cell viability assays
In some experiments cell viability was determined by
XTT assay. Briefly, CaOV3 or OVCAR3 cells were plated
at 20,000 cells/well in 96-well plates in complete
medium. The next day, cells (confluence 60-70%) were
exposed to medium containing OPG or ascites (10%) for
1 h after which TRAIL was added to the medium for
total of 48 h. At the termination of the experiment, the
culture media was removed and a mixture of PBS and
fresh media (without phenol red) containing phenazine
methosulfate and XTT was added for 30 min at room
temperature. The O.D. was determined using a micro-
plate reader at 450 nm (TecanSunrise, Research Triangle
Park, NC). The percentage of cell viability was defined
as the relative absorbance of TRAIL-treated cells versus
untreated (no TRAIL, no ascites, no OPG) cells. Cells
were also challenged with TRAIL in fresh medium sup-
plemented with ascites (10%) and. To neutralize OPG in
ascites, anti-OPG antibodies (10 μg/ml) were incubated
for 1 h with ascites. The OPG-neutralized ascites were
then added to cells and they were challenged with
TRAIL for 48 h. In other experiments, cells were chal-
lenged with increasing concentration of TRAIL (0 to
50 ng/ml) in either fresh medium or medium containing
ascites (10%) and the concentration of TRAIL allowing
50% cell viability was defined as the IC50. The anti-
apoptotic activity of OC ascites was expressed as TRAIL
IC50 with ascites/IC50 without ascites. Protective ascites
were defined as those with a ratio ≥ 2.
For clonogenic survival assays, cells were plated into
25 mm2 tissue culture plates in standard medium. The
next day, cells were incubated for 90 min in medium
containing OPG (25 ng/ml) or ascites (10%) and TRAIL
(50 ng/ml) was added to the medium for either 3 h or
48 h. Cells were then washed with PBS and incubated in
fresh medium into 6-well plates at the different densities
for 14 days. Cells were fixed and stained with crystalviolet. The number of colonies, consisting of > 50 cells,
in triplicate was counted.
Apoptosis
Cells were incubated in medium containing OPG
(25 ng/ml) for 1 h after which TRAIL (50 ng/m) was
added to the medium and cells were incubated for 24 h.
The release of nucleosomal DNA into the cytoplasm as
a measure of apoptosis was determined using the Cell
Death Detection ELISA Kit (Roche, Laval, Québec,
Canada) according to the manufacturer’s instruction.
The absorbance was determined using a microplate
reader at 410 nm.
Determination of OPG concentration by ELISA
OPG levels were determined using an ELISA from E
Biosciences (San Diego, CA). The assays were performed
in duplicate according to the manufacturer’s protocols.
The detection threshold was 4.5 pg/ml for OPG and the
intra-assay variability was 4.3-7.9%.
Statistical analysis
Experiments were performed in triplicate, and data pre-
sented as mean ± SD. Student’s paired t-test was used to
analyze differences between the treatment conditions and
their controls. Dose responses were compared by ANOVA
test. The threshold for statistical significance is P < 0.05.
Results
OPG and malignant ascites protects OC cells from
TRAIL-induced apoptosis
Because OPG protects prostate and breast cancer cells
from TRAIL-induced apoptosis [22-28], we hypothesized
that OPG could also attenuate TRAIL-induced apoptosis
in OC cells. To this end, we performed dose–response
experiments with exposure of OPG at concentrations
ranging from 0 to 100 ng/ml for 48 h in TRAIL treated
CaOV3 cells. Cell viability was assessed using an XTT
assay. As shown in Figure 1A, OPG significantly decreased
TRAIL-induced cell death at concentrations > 2.5 ng/ml
(P < 0.001). Exposure of CaOV3 cells to ascites OVC508,
which contain 3570 pg/ml of OPG, also attenuated
TRAIL-induced cell death, consistent with previous find-
ings [32,33]. When CaOV3 cells were treated with in-
creasing concentrations of TRAIL (0 to 50 ng/ml), OPG
(25 ng/ml) was effective to significantly (P < 0.001) attenu-
ate TRAIL-induced cell death (Figure 1B). To extend these
findings, CaOV3 cells were challenged with 10 ng/ml of
TRAIL for 3 h and 48 h in the presence or absence of
OPG (25 ng/ml). Cell viability was assessed by counting
the number of viable colonies after two weeks. Exposure
to OPG significantly increased the number of colonies
when compared to TRAIL-only treated cells (Figure 1C).
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Figure 1 (See legend on next page.)
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Figure 1 TRAIL-induced apoptosis can be attenuated by OPG and malignant ascites. (A) CaOV3 cells were challenged with TRAIL
(10 ng/ml) and increasing concentrations of recombinant OPG was added to the cultures. Cell viability was assessed after 48 h by XTT assay and
was expressed as the percentage relative to control cells. (B) CaOV3 cells were challenged with increasing concentrations of TRAIL and a fixed
dose of OPG (25 ng/ml for 48 h after which cell viability was assessed. (C) CaOV3 cells were challenged with TRAIL (10 ng/ml) and OPG (25 ng/ml)
for either 3 h or 48 h. The cells were washed and fresh medium was added. Viable colonies were counted after 14 days and data were expressed
as% of colonies in control (untreated) cells. (D) OVCAR3 cells were challenged with TRAIL (50 ng/ml) and OPG (25 ng/ml) for 48 h and assessed as
above. (E) CaOV3 cells were challenged with TRAIL (10 ng/ml) and either OVC508 or OVC551 ascites (10% v/v) or OPG (25 ng/ml) for 48 h and
viable colonies were counted after 14 days. CaOV3 cells (F), OVCAR3 cells (G) and primary tumor cells OVC238A (H) were challenged with either
OPG (25 to 500 ng/ml), TRAIL (10 to 100 ng/ml) or both and apoptosis was assessed 24 h later. Apoptosis was expressed as fold increased relative
to control (untreated) cells. Data are expressed as means of triplicates from three independent experiments ± SD. * P < 0.01, ** P < 0.001 compared
to control.
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cells (Figure 1D). Exposure to OPG also significantly
increased the number of viable colonies after two weeks. To
confirm that ascites attenuate TRAIL-induced cell death,
colony forming assays were performed with OVC508 and
OVC551 ascites (3570 pg/ml and 19620 pg/ml of OPG
respectively) and showed a level of protection from
TRAIL-induced cell death similar to OPG (25 ng/ml)
(Figure 1E). In agreement with these findings, OPG atte-
nuated TRAIL-induced apoptosis in CaOV3 cells, as
measured by oligosomal DNA fragmentation (Figure 1F).
Apoptosis was measured in OVCAR3 cells exposed to
TRAIL and OPG and consistently showed that OPG atte-
nuated TRAIL-induced apoptosis (Figure 1G). To further
extend these observations, primary tumor cells were iso-
lated from the ascites of four patients with advanced OC
and OPG protection was consistently seen in these cells
(Figure 1H). Taken together, these data suggest that OPG



























Figure 2 Conditioned medium from OC cells do not suppress TRAIL-i
(50 ng/ml) and either fresh medium (Fresh), 5-25% SKOV3 or COV2 conditio
viability was determined by XTT assay. Data are expressed as means of trip
compared to control. (B) OPG concentrations in the cell supernatant of TRA
lines SKOV3 and COV2, and human primary ovarian tumor cells OVC215A, O
after culture of confluent cells for 48 h.addition, they suggest that OPG could be one of the
determinants in ascites that confer protection against
TRAIL.
It was previously shown that tumor cells may secrete
sufficient levels of OPG in the medium to attenuate
TRAIL-induced apoptosis [22,26-28]. Thus, CaOV3 cells
were cultured with conditioned media (96 h) from the
TRAIL-resistant OC cell line COV2 and SKOV3 in the
presence of TRAIL and cell viability was assessed by
XTT assay. The hypothesis was that TRAIL-resistant OC
cell lines could secrete enough OPG in the medium to
confer resistance to TRAIL. However, in contrast to re-
combinant OPG (25 ng /ml) and ascites (10%), condi-
tioned medium from COV2 and SKOV3 cells (5% to
25%) failed to attenuate TRAIL-induced cell death
(Figure 2A). The data suggest that TRAIL-resistant OC
cells do not produce enough OPG in vitro to suppress
TRAIL-induced cell death in CaOV3 cells. An ELISA














nduced cell death. CaOV3 cells were challenged with TRAIL
ned medium, or OPG (25 ng/ml) or ascites (10%) for 48 h, and cell
licates from three independent experiments ± SD. ** P < 0.001
IL sensitive OC cell lines CaOV3 and OVCAR3, TRAIL resistant OC cell
VC238A, OVC285A, OVC327A and OVC346A were measured by ELISA
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and into the medium of primary ovarian tumor cells
when cultured for 48 h (Figure 2B).
Presence of OPG in malignant ascites from patients with
advanced OC
To assess whether OPG could be one of the determi-
nants in ascites that contribute to ascites-mediated in-
hibition of TRAIL-induced apoptosis, we measured
OPG by performing ELISA analysis of the acellular frac-
tion of ascites obtained at the time of the initial surgery
from 40 patients with OC (Additional file 2: Table S1).
Most (70%) were serous sub-types and had advanced
(stage III/IV) disease. ELISA analysis demonstrated that
ascites contain OPG at very different levels (median 11.2
nM, range: 0.18-453 nM). This median OPG concentra-
tion in OC ascites (11.2 nM) is however lower than the
apparent dissociation constant for the binding of OPG
to TRAIL that is around 400 nM [19].
To determine whether there is a correlation between
OPG levels in ascites and their ability to attenuate
TRAIL-induced apoptosis, TRAIL IC50 was determined
from cell viability curves done with the CaOV3 cell line.
The anti-apoptotic activity of OC ascites was expressed
as TRAIL IC50 with ascites/IC50 without ascites. Protect-
ive ascites were defined as those with a ratio ≥ 2. The
protein concentration was not significantly different in
protective and non-protective ascites (data not shown).
As shown in Figure 3A, the median level of OPG was
significantly higher in ascites with anti-apoptotic activity
as compared to those without (P < 0.001). Furthermore,
there was a positive correlation between OPG levels in
















































Figure 3 Concentration of OPG in ascites according to their anti-apop
OC in non-protective versus protective ascites against TRAIL as defined in M
of OPG levels in ascites versus the anti-apoptotic activity of ascites. The corwith correlation coefficient (r) of 0.431 (Figure 3B).
These data support the hypothesis that OPG is one of
the factors that promote ascites-mediated attenuation of
TRAIL-induced apoptosis.Ascites-mediated attenuation of TRAIL-induced apoptosis
is OPG-independent
Although malignant ascites and OPG both attenuate
TRAIL-induced apoptosis, it is unclear whether OPG
contributes to the inhibition of TRAIL-induced apop-
tosis by ascites. We thus used a blocking antibody to
neutralize OPG in ascites. CaOV3 cells were untreated
(control), treated with TRAIL alone or with a combin-
ation of TRAIL with OPG (25 ng/ml) in the presence or
absence of an OPG blocking antibody, and cell viability
was assessed by XTT. As expected, the addition of the
OPG blocking antibody completely abrogated the pro-
tective effect of OPG against TRAIL (Figure 4A). In con-
trast, the addition of the OPG blocking antibody had
no effect on the anti-apoptotic activity of OVC508
(Figure 4B) and OVC551 (Figure 4C) ascites despite
the fact that 62-66% of the OPG in ascites was neutra-
lized (Figure 4D). To confirm these data, we performed
colony forming assays. In agreement with the XTT
assays, although exposure to OVC508 and OVC551
ascites significantly inhibited TRAIL-induced cytotox-
icity in CaOV3 cells, the addition of the anti-OPG
antibody failed to alter the anti-apoptotic effect of
OVC508 and OVC551 ascites (Figure 4E). Altogether,
the results suggest that OPG is not a critical compo-
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Figure 4 The anti-apoptotic effect of ascites cannot be reversed by OPG neutralizing antibodies. (A) CaOV3 cells were challenged with
increasing concentrations of TRAIL and OPG (25 ng/ml) in the presence or absence of anti-OPG antibodies (10 μg/ml) for 48 h. Cell viability was
determined by XTT assay and expressed as the percentage relative to control (untreated) cells. CaOV3 cells were challenged with TRAIL, OVC508
ascites (10%) (B) or OVC551 ascites (10%) (C), in the presence or absence of anti-OPG antibodies (10 μg/ml) for 48 h. Cell viability was assessed as
above. (D) OVC508 ascites was incubated with anti-OPG antibodies (10 μg/ml) for up to 6 h. Protein G agarose was then added for 1 h and
centrifuged and OPG levels were determined in the supernatant by ELISA. (E) CaOV3 cells were challenged with TRAIL (10 ng/ml), ascites (10%)
and anti-OPG (10 μg/ml) for 48 h. The cells were washed and fresh medium was added. Viable colonies were counted after 14 days and data
were expressed as% of colonies in control (untreated) cells. Data are expressed as means of triplicates from three independent experiments ± SD.
NS indicates that differences did not reach statistical significance with P > 0.05.
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In this study, we tested the hypothesis that the anti-
apoptotic effect of malignant ascites against TRAIL
could be related to the presence of high levels of OPG.
Previous studies have established that OPG acts as a sur-
vival factor, at least in vitro, by attenuating TRAIL-
induced apoptosis in colon, breast and prostate cancer
cells [22-29]. In addition, OPG appears to be a critical
component of the bone microenvironment. Our in vitro
results demonstrated that recombinant OPG protected
CaOV3 and OVCAR3 cell lines from TRAIL-induced
apoptosis in a dose-dependent manner. Furthermore,
tumor cells isolated from malignant ascites were also
protected from TRAIL-induced apoptosis by the
addition of OPG, indicating that OPG acts as a survival
factor for OC cells. Minimal concentrations of OPG
required to significantly inhibit TRAIL-induced apop-
tosis in OC cell lines were in the order of 10 ng/ml. The
level of OPG present in malignant ascites varied consid-
erably between ascites and in many instances was too
low (< 1 ng/ml) to counteract the apoptotic action of
TRAIL. Nonetheless, we found a positive correlation
between the level of OPG present in ascites and the
ability of ascites to attenuate TRAIL-induced apoptosis.
These observations may support the proposition that
OPG, as an extracellular factor in malignant ascites, may
function as a survival factor for OC cells.
The anti-apoptotic effect of recombinant OPG could
be completely reversed by cotreatment with an anti-
OPG blocking antibody whereas the antibody itself had
no effect on apoptosis levels in OC cells (data not
shown). CaOV3 cells treated with TRAIL in the presence
of OVC508 and OVC551 ascites containing 3.6 ng/ml
and 19,6 ng/ml respectively of OPG showed lower level
of cell death compared to those treated with TRAIL
alone. Although this anti-apoptotic effect of ascites was
hypothesized to be due, at least in part, to the presence
of OPG, incubation of CaOV3 cells with the OPG block-
ing antibody had no effect on the anti-apoptotic prop-
erty of OVC508 and OVC551, suggesting that OPG is
not a critical survival factor in ascites.
The source of OPG in malignant ascites remains to be
established but it has been shown that a number of dif-
ferent cell types are capable of producing OPG. Data
from other studies suggest that prostate and breast
cancer cells can produce OPG [22,23,25-28]. Our data
demonstrated that OC cancer cell lines and primary
tumor cells isolated from ascites also produce OPG with
concentration ranging from 30 to 1031 pg/ml. These
concentrations were well within the range of those
found in malignant ascites. The overall contribution of
the various cell populations to the total OPG levels in
ascites will depend on the number of tumor cells in rela-
tion to other cells. Stromal cells have been shown to bea significant source of OPG [25,37]. In this context, it
could be speculated that, in addition to tumor cells,
human peritoneal mesothelial cells, which are an im-
portant constituent of malignant ascites, could also be a
source of OPG.
In summary, although most malignant ascites have
measurable OPG level, these concentrations do not
reach the level required to attenuate TRAIL-induced
apoptosis in the majority of ascites. In addition, blockade
of endogenous OPG in ascites do not affect their anti-
apoptotic activity. Thus, the presence of OPG in malig-
nant ascites by itself is an unlikely mechanism by which
ascites attenuate TRAIL-induced apoptosis.
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